Index
RUT
P/E
40.52
EPS (ttm)
1.94
Insider Own
0.36%
Shs Outstand
54.90M
Perf Week
-1.80%
Market Cap
4.31B
Forward P/E
16.95
EPS next Y
4.63
Insider Trans
-1.49%
Shs Float
54.73M
Perf Month
7.65%
Enterprise Value
4.12B
PEG
1.82
EPS next Q
1.09
Inst Own
110.09%
Perf Quarter
23.56%
Income
107.13M
P/S
3.01
EPS this Y
8.95%
Inst Trans
6.75%
Perf Half Y
24.45%
Sales
1.43B
P/B
3.56
EPS next Y
9.00%
ROA
4.22%
Perf YTD
27.58%
Book/sh
22.06
P/C
7.99
EPS next 5Y
9.29%
ROE
9.54%
52W High
80.96 -3.03%
Perf Year
73.79%
Cash/sh
9.82
P/FCF
26.78
EPS past 3/5Y
-40.20% 9.06%
ROIC
6.94%
52W Low
41.01 91.39%
Perf 3Y
57.76%
Dividend Est.
-
EV/EBITDA
15.08
Sales past 3/5Y
10.75% 8.24%
Gross Margin
67.56%
Volatility
2.72% 3.28%
Perf 5Y
-4.56%
Dividend TTM
-
EV/Sales
2.87
EPS Y/Y TTM
148.08%
Oper. Margin
14.82%
ATR (14)
2.56
Perf 10Y
60.20%
Dividend Ex-Date
-
Quick Ratio
1.11
Sales Y/Y TTM
12.40%
Profit Margin
7.47%
RSI (14)
63.29
Dividend Gr. 3/5Y
- -
Current Ratio
1.33
EPS Q/Q
106.63%
SMA20
3.70%
Beta
0.86
Payout
-
Debt/Eq
0.28
Sales Q/Q
14.33%
SMA50
12.23%
Rel Volume
1.80
Prev Close
78.50
Employees
3300
LT Debt/Eq
0.27
SMA200
25.43%
Avg Volume
791.33K
Price
78.50
IPO
Feb 11, 1993
Option/Short
Yes / Yes
Trades
Volume
1,426,485
Change
0.00%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-19-25 Initiated KeyBanc Capital Markets
Overweight
$81
Oct-01-25 Downgrade Goldman
Buy → Neutral
$55
May-20-25 Upgrade Wolfe Research
Peer Perform → Outperform
$60
Feb-26-25 Downgrade Wolfe Research
Outperform → Peer Perform
Oct-04-24 Initiated Goldman
Buy
$65
Sep-17-24 Upgrade Robert W. Baird
Neutral → Outperform
$55 → $66
Mar-20-24 Reiterated Needham
Buy
Feb-20-24 Upgrade Mizuho
Neutral → Buy
$60 → $70
Sep-06-23 Initiated HSBC Securities
Hold
$52
Jul-19-23 Initiated Robert W. Baird
Neutral
$56
Apr-14-23 Initiated Mizuho
Neutral
$48
Dec-21-22 Initiated Barclays
Equal Weight
$62
Apr-06-22 Initiated Wolfe Research
Outperform
$95
Feb-24-22 Upgrade UBS
Neutral → Buy
$96
Dec-03-21 Initiated Goldman
Buy
$108
Aug-20-21 Reiterated Needham
Buy
$104 → $117
Jul-20-21 Upgrade Needham
Hold → Buy
$93
Mar-03-21 Downgrade Berenberg
Buy → Hold
$84
Jan-05-21 Downgrade Needham
Buy → Hold
Sep-02-20 Initiated Robert W. Baird
Outperform
$55
Show Previous Ratings
Jun-16-26 10:57AM
Jun-11-26 01:44PM
Jun-05-26 09:00AM
May-21-26 09:15AM
May-19-26 08:00AM
04:52PM
Loading…
May-06-26 04:52PM
08:32AM
06:11AM
06:00AM
Apr-20-26 05:05PM
Mar-27-26 10:15AM
Mar-25-26 09:00AM
Mar-19-26 08:30AM
Mar-10-26 11:40AM
11:39AM
11:21AM
Loading…
11:21AM
Mar-05-26 12:00PM
Feb-25-26 03:29PM
02:28PM
02:01PM
12:36PM
12:30PM
12:15PM
06:07AM
(Associated Press Finance)
06:00AM
Feb-24-26 07:30PM
Feb-02-26 02:51PM
(Investor's Business Daily)
Jan-30-26 02:31PM
Jan-29-26 09:03AM
(Investor's Business Daily)
08:21AM
(Investor's Business Daily)
08:03AM
Loading…
08:03AM
(Investor's Business Daily)
Jan-28-26 05:10PM
(Investor's Business Daily)
01:46PM
(Investor's Business Daily)
Jan-20-26 09:00AM
Dec-23-25 09:00AM
Dec-03-25 09:00AM
Dec-02-25 09:00AM
Nov-25-25 09:00AM
Nov-24-25 07:21PM
(Morningstar Research)
+9.35%
09:00AM
Nov-13-25 07:40PM
Nov-12-25 03:26PM
Nov-06-25 10:00PM
Nov-05-25 07:10AM
06:13AM
(Associated Press Finance)
06:00AM
Oct-31-25 09:40AM
Oct-23-25 09:00AM
Oct-08-25 09:00AM
Oct-07-25 09:00AM
Oct-02-25 09:10AM
Oct-01-25 09:44AM
Sep-30-25 09:40AM
Sep-08-25 04:34PM
Sep-04-25 09:00AM
Aug-22-25 09:00AM
Aug-18-25 09:00AM
Aug-15-25 10:10AM
Aug-06-25 07:35PM
(Morningstar Research)
+11.15%
07:10AM
06:11AM
(Associated Press Finance)
06:00AM
Aug-05-25 07:45AM
Aug-04-25 10:02AM
Jul-30-25 11:49AM
Jul-29-25 04:38AM
Jul-16-25 09:39AM
Jul-11-25 08:12PM
(Morningstar Research)
-5.01%
Jul-09-25 09:00AM
Jun-25-25 11:37AM
Jun-10-25 08:33PM
Jun-06-25 09:58AM
Jun-05-25 08:15AM
08:00AM
Jun-04-25 08:00AM
May-15-25 08:00AM
May-08-25 03:10AM
May-07-25 11:31AM
(Morningstar Research)
+23.72%
07:15AM
06:14AM
(Associated Press Finance)
06:00AM
05:45AM
May-06-25 06:05PM
May-01-25 05:15PM
Apr-25-25 04:30PM
Apr-14-25 09:51AM
Apr-10-25 04:32AM
Mar-26-25 08:00AM
Mar-04-25 11:56PM
10:12PM
Feb-26-25 02:04AM
Feb-25-25 08:32PM
(Morningstar Research)
-15.76%
07:10AM
06:10AM
(Associated Press Finance)
06:00AM
Feb-21-25 12:39PM
09:00AM
Feb-13-25 05:32AM
Jan-23-25 10:25AM
Jan-21-25 09:00AM
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the following segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support (ACS). The Cardiopulmonary segment is involved in the design, development, manufacture, marketing and selling of cardiopulmonary products. The Neuromodulation segment is associated in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating DRE and DTD. The ACS segment deals with the design, development, manufacture, marketing and selling of temporary life support products. The company was founded in 1987 and is headquartered in London, the United Kingdom.
CEO & Director Mr. Vladimir A. Makatsaria
Chief Financial Officer Mr. Alex Shvartsburg C.M.A.
Chief Human Resources Officer Ms. Natalia Kozmina
Chief Innovation Officer Mr. Ahmet Tezel Ph.D.
VP & Chief Accounting Officer Ms. Lindsey Little
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
WILVER PETER M Director Jun 15 '26 Option Exercise 0.00 4,042 0 10,780 Jun 17 04:09 PM SCHERMERHORN TODD C Director Jun 15 '26 Option Exercise 0.00 4,042 0 13,105 Jun 17 04:09 PM Bianchi Francesco Director Jun 15 '26 Option Exercise 0.00 4,042 0 11,270 Jun 17 04:09 PM Bianchi Francesco Director Jun 15 '26 Sale 80.19 1,200 96,228 9,584 Jun 17 04:09 PM PODLOGAR SUSAN M Director Jun 15 '26 Option Exercise 0.00 4,042 0 6,128 Jun 17 04:09 PM Barry James Christopher Director Jun 15 '26 Option Exercise 0.00 4,042 0 8,404 Jun 17 04:09 PM Tezel Ahmet Chief Innovation Officer Jun 15 '26 Option Exercise 0.00 2,965 0 7,122 Jun 17 04:09 PM KOZY WILLIAM A Director Jun 15 '26 Option Exercise 0.00 5,681 0 38,248 Jun 17 04:09 PM Enxing Seng Stacy Director Jun 15 '26 Option Exercise 0.00 4,042 0 15,793 Jun 17 04:08 PM Story Brooke Director Jun 15 '26 Option Exercise 0.00 4,042 0 10,274 Jun 17 04:08 PM Zurbay Donald Director Jun 15 '26 Option Exercise 0.00 2,560 0 2,560 Jun 17 04:08 PM Bianchi Francesco Officer Jun 15 '26 Proposed Sale 80.19 1,200 96,228 Jun 15 04:56 PM Bianchi Francesco Director May 26 '26 Sale 75.75 1,800 136,350 7,228 May 27 04:51 PM Bianchi Francesco Officer May 26 '26 Proposed Sale 75.75 1,800 136,350 May 26 04:37 PM Tezel Ahmet Chief Innovation Officer Mar 30 '26 Option Exercise 0.00 3,408 0 5,343 Apr 01 05:20 PM Poletti Franco President, Cardiopulmonary Mar 30 '26 Option Exercise 0.00 3,184 0 12,125 Apr 01 05:20 PM Shvartsburg Alex Chief Financial Officer Mar 30 '26 Option Exercise 0.00 30,835 0 57,515 Apr 01 05:20 PM Makatsaria Vladimir Chief Executive Officer Mar 30 '26 Option Exercise 0.00 21,042 0 25,326 Apr 01 05:20 PM Bolton Stephanie President, Global Epilepsy Mar 30 '26 Option Exercise 0.00 17,815 0 30,566 Apr 01 05:20 PM Kozmina Natalia Chief Human Resources Officer Mar 30 '26 Option Exercise 0.00 6,389 0 6,389 Apr 01 05:20 PM Poletti Franco President, Cardiopulmonary Mar 11 '26 Option Exercise 57.60 2,140 123,264 10,990 Mar 13 05:25 PM Poletti Franco President, Cardiopulmonary Dec 15 '25 Option Exercise 0.00 967 0 9,266 Dec 17 04:06 PM PODLOGAR SUSAN M Director Dec 15 '25 Option Exercise 0.00 2,355 0 2,355 Dec 17 04:06 PM Hutchinson Michael Damon SVP, CLO and Company Secretary Dec 15 '25 Option Exercise 0.00 2,254 0 7,920 Dec 17 04:06 PM Story Brooke Director Nov 18 '25 Sale 53.94 250 13,485 6,232 Nov 19 03:57 PM Story Brooke Director Nov 18 '25 Proposed Sale 53.94 250 13,485 Nov 18 04:51 PM Poletti Franco President, Cardiopulmonary Sep 15 '25 Option Exercise 0.00 643 0 8,576 Sep 17 04:05 PM Bianchi Francesco Director Aug 25 '25 Sale 56.50 1,500 84,750 9,028 Aug 27 04:17 PM Bianchi Francesco Director Aug 25 '25 Proposed Sale 56.50 1,500 84,750 Aug 25 04:26 PM
